Please login to the form below

Not currently logged in
Email:
Password:

ADC

This page shows the latest ADC news and features for those working in and with pharma, biotech and healthcare.

Seattle Genetics makes case for Padcev plus Keytruda in first-line bladder cancer

Seattle Genetics makes case for Padcev plus Keytruda in first-line bladder cancer

Now, Seattle and Astellas are looking to expand the use of the ADC into earlier lines of therapy, and they are making their case for a combination therapy of the drug.

Latest news

More from news
Approximately 2 fully matching, plus 74 partially matching documents found.

Latest Intelligence

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    10. Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) is also an ADC that targets HER2. ... Kadcyla, the only other anti-HER2 ADC in this market, is a direct competitor and differentiation versus this established drug will be key.

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    The HER2-targeting antibody-drug conjugate (ADC) combines the HER2-targeting of Roche’s blockbuster breast cancer therapy Herceptin (trastuzumab) with a cell-killing chemotherapy component designed to improve its ability ... Roche already has a

  • European biotech: a new generation of leaders emerges European biotech: a new generation of leaders emerges

    In addition to traditional antibodies, the pipeline also includes antibody drug conjugates (ADCs), bispecific antibodies created from its DuoBody technology platform, and antibodies created with its HexaBody technology.

  • Deal Watch February 2017 Deal Watch February 2017

    Competitive deal tendering and investor revolt. One of the largest therapeutic deals in February was the Immunomedics licence with Seattle Genetics for a phase 2 stage antibody drug conjugate (ADC), sacituzumab ... As an ADC IMMU-132 contains SN-38,

  • Deal Watch January 2017 Deal Watch January 2017

    465. Abzena. Not disclosed. Licence. ThioBridge ADC linker technology. 300. Domain Therapeutics.

More from intelligence
Approximately 0 fully matching, plus 20 partially matching documents found.

Latest appointments

  • Glythera strengthens its scientific advisory board and appoints CSO Glythera strengthens its scientific advisory board and appoints CSO

    Dr Lutz was previously vice president of translation research and development at ImmunoGen, where he was responsible for all early-stage ADC development programmes. ... Dr Dave Simpson, chief executive officer of Glythera, said: “Robert Lutz’s

  • Glythera appoints Dr Mike Owen Glythera appoints Dr Mike Owen

    His experience in advancing scientific discoveries from the lab to commercialisation will be invaluable in helping us fully exploit our unique ADC platform, both in the development of our proprietary product

  • ADC Therapeutics expands team ADC Therapeutics expands team

    Appointments preceed its first antibody drug conjugate trials. ADC Therapeutics has significantly expanded its team head of putting its first antibody drug conjugates (ADCs) into clinical development. ... Michael Forer, CEO of ADC Therapeutics, said:

  • ImmunoGen hires VP product strategy ImmunoGen hires VP product strategy

    These programmes focus on antibody-drug conjugates (ADCs) to target cancers. The most successful of these ADCs so far is Kadcyla, which ImmunoGen developed with Genentech, now a part of Roche.

  • CytomX makes senior changes following Pfizer deal CytomX makes senior changes following Pfizer deal

    conjugates (ADCs) for cancer. .

More from appointments
Approximately 1 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics